Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have aggressive CD20-positive B-cell non-Hodgkin lymphoma that has grown after at least two prior treatments, including an anti-CD20 medicine and chemotherapy (alkylating agent)
- Your scans show measurable lymphoma spots that can be measured on imaging
- Your energy/performance is good enough for study visits (ECOG 0 or 1)
- Your blood counts plus kidney and liver function meet the lab limits in the study protocol
- You can provide tumor tissue for testing (either archived tissue or a new biopsy if a spot is available and safe)
- You have not had certain prior transplants or prior treatments with odronextamab or similar anti-CD20 x anti-CD3 medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Hear when a new B-cell Non-Hodgkins Lymphoma (B-NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.